Abstract: A lifting and walking aid having a framework (1) constructed of a lower horizontal frame (2a-2c) provided with small casters (9), an upper horizontal frame (2d-2f) provided with lifting means, and a vertical frame (2g-2n) secured to both the upper and lower horizontal frames (2a-2c) and (2d-2f). The framework comprises a plurality of substantially rectilinear tubular members (2a-2y) which are connected to each other so as to allow for a quick disassembling of the framework (1).

Abstract: A process for the manufacture of a composite laminate which includes a thermoplastic film laminated to a substrate. The front surface of the film has a regular embossed pattern of protrusions which have a height in the range of 0.5 to 10 microns and a separation in the range 20 to 400 microns. The rear surface of the film confronts and is bonded to the substrate. The manufacturing process of the composite includes the steps of applying a layer of a melt adhesive between the rear surface of the film having a regular embossed pattern on its front surface and the substrate to form a composite, and running the composite of the film, the layer and the substrate between nip rollers to apply pressure to the composite whilst the adhesive is in a heated condition, so as to effect thermal lamination of the film to the substrate.

Abstract: In the manufacture of viscose, and an elongate cellulose member such as standard viscose rayon fibre, with reduced alkali ratio from dissolving-grade cellulose such as wood pulp by irradiation with a high energy beam at a dose of 1-30 kGy, steeping in aqueous sodium hydroxide, pressing to form alkali cellulose, xanthating to form cellulose xanthate, dissolving in aqueous liquor to form viscose and (when elongate cellulose members are required) extruding through a die into an acid bath for coagulation and regeneration to form an elongate cellulose member which is then washed and dried, viscose filtration can be improved by including in the dissolving liquor for the cellulose xanthate an amount of from 200 to 10000 ppm by weight of a salt which consists of alkali metal or ammonium cations and anions of a strong acid.

Abstract: Each link plate of a low noise silent chain has an inside meshing surface formed on the inside flank of each link tooth. The inside meshing surface includes a convexly arcuate mesh start portion disposed on a tip side of each link tooth, and a convexly arcuate mesh guide portion disposed on a root side of each link tooth. The arcuate mesh guide portion has a radius of curvature and a circular arc length which are greater than a radius of curvature and a circular arc length, respectively, of the convexly arcuate mesh start portion. When the silent chain engages a sprocket, the engagement proceeds smoothly and continuously from the inside meshing surface to the outside meshing surface. This contributes to the reduction of the noise level of the silent chain as a whole through suppression of meshing sound of the outside meshing surface and vibratory chain noise.

Abstract: An electric resistance high temperature vacuum furnace having radiant heating units evenly spaced around the sides and ends of the furnace hot zone. Pairs of units are automatically regulated both radially and longitudinally according to the temperature required by the workload in the hot zone. The units each comprise parallel aligned elements electrically connected in series at their one ends. Each element has lengthwise surfaces angularly disposed from each other to form a beam structure of high section modulus for stiffness and resistance to sagging. Also, the angles of the element surfaces facing a heat-reflective assembly substantially enable all of the energy radiated toward the assembly to be reflected into the hot zone in addition to the direct radiation from the surfaces facing the hot zone. The furnace includes a re-circulating cooling system for rapid cooling of the furnace and workload.

Abstract: To provide an optically transparent film containing 0.01 to 20% by weight glass forming oxide consisting of Nb2O5, V2O5, B2O3, SiO2, and P2O6; 0.01 to 20% by weight Al2O3 or Ga2O3; and 0.01 to 5% by weight hard oxide of ZrO2 and TiO2 as required; balance being ZnO, and a sputtering target for forming such a film. This sputtering target reduces occurrence of particles during sputtering, decreases the number of interruption or discontinuance of sputtering to improve production efficiency, and forms a protective film for optical disks with large transmittance and low reflectance.

Abstract: Two stable cytolytic T lymphocyte cell lines and a clone are established from two primary colorectal carcinoma patients. A method for generating stable anti-colorectal carcinoma CTL clones and cell lines includes the step of stimulating the lymphocytes of a patient with minimal or no clinical evidence of colorectal carcinoma in culture with irradiated autologous primary colorectal carcinoma tumor cells, interleukin-2, and either autologous lymphocytes or autologous EBV-B cells.

Abstract: A composition which elicits antibodies to multiple known variants of Tat protein of HIV-1 of both the B and non-B clades contains the peptide R1-Asp-Pro-Asn-Leu-Asp-Pro-Trp-Asn-R2 SEQ ID NO: 23, and preferably an additional at least two variants of a peptide or polypeptide of the formula: R1-Asp-Pro-Y7-Leu-X9-Pro-Trp-Z12-R2 (SEQ ID NO: 8). In this composition, at least one of the two variants contains Arg at Y7 and Lys at Z12, and in at least a second of the two variants Y7 is Asn and Z12 is Asn. Vaccinal and pharmaceutical compositions can contain one or more such peptides associated with carrier proteins, associated in multiple antigenic peptides or as part of recombinant proteins. Diagnostic compositions and uses are described for assessing the immune status of vaccinated patients.

Abstract: A composition which elicits antibodies to greater than 95%, and even greater than 99%, of the known variants of HIV-1 Tat protein contains at least one peptide or polypeptide of the formula of Epitope I (based on amino acids 2-10 of HIV-1 Tat consensus sequence) and optionally one or more of a peptide or polypeptide of Epitope II (based on amino acids 41 to 51 of that sequence), of Epitope III (based on amino acids 52-62 of that sequence), or of Epitope IV (based on amino acids 62 through 72 of that sequence with a C-termninal Pro). Vaccinal and pharmaceutical compositions can contain one or more such peptides associated with carrier proteins, in multiple antigenic peptides or as part of recombinant proteins. Various combinations of the Epitope I through IV peptides can provide other compositions useful in eliciting anti-Tat antibodies which cross-react with multiple strains and variants of HIV-1 Tat protein.

Abstract: The present invention relates to fire-resistant hydraulic fluids. More particularly, the invention relates to fire-resistant hydraulic fluid compositions comprising the combination of a trialkoxyalkyl-phosphate, a diluent selected from the group consisting of a natural triglyceride, a synthetic ester, and a polypropylene glycol, and a high molecular weight polymer.

Abstract: This invention relates to compounds which are agonists of the progesterone receptor which have the general structure: wherein: R1, R2, R3, R4, R5 and Q1 are as defined herein, or a pharmaceutically acceptable salt thereof, as well as methods of using these compounds to induce contraception or treat progesterone-related carcinomas and adenocarcinomas.

Abstract: Cellulosic fibrids can be made by mixing together under turbulent conditions viscose and a coagulating and regenerating liquor containing preformed fibrids to form a suspension of fibrids in a spent liquor, and collecting the fibrids from the spent liquor.

Abstract: A papermaking felt which offers excellent elasticity over a long duration comprises a base body (2) and batt layers (3), and a film layer (5) with elongate ridges (4) having their orientation in the CMD direction. The film is arranged in the base body, in the batt layers, or between the layers. The papermaking felt is capable of running flexibly and smoothly in a winding path of a papermaking machine, and is highly resistant to flattening through fatigue, even if subjected to repeated compression under the nip pressure.

Abstract: This invention provides compounds of Formula (I): wherein R1 and R2 may be single substituents or fused to form spirocyclic or hetero-spirocyclic rings; R3 is H, OH, NH2, C1 to C6 alkyl, substituted C1 to C6 alkyl, C3 to C6 alkenyl, substituted C1 to C6 alkenyl, alkynyl, or substituted alkynyl, CORC; RC is H, C1 to C3 alkyl, substituted C1 to C3 alkyl, aryl, substituted aryl, C1 to C3 alkoxy, substituted C1 to C3 alkoxy, C1 to C3 aminoalkyl, or substituted C1 to C3 aminoalkyl; R4 is H, halogen, CN, NO2, C1 to C6 alkyl, substituted C1 to C6 alkyl, alkynyl, or substituted alkynyl, C1 to C6 alkoxy, substituted C1 to C6 alkoxy, amino, C1 to C6 aminoalkyl, or substituted C1 to C6 aminoalkyl; and R5 is selected from a trisubstituted benzene ring of a five or six membered ring with 1, 2, or 3 heteroatoms from the group including O, S, SO, SO2 or NR6 and containing one or two independent substituents from the group including H, halogen, CN, N02, amino, and C1 to C3 alkyl, C1 to C3 alkoxy, C1 to C3 a

Abstract: Cellulosic fibrids can be made by mixing together under turbulent conditions viscose and a coagulating and regenerating liquor so as to form a suspension of soft macroscopic cellulosic particles in a spent liquor, collecting the particles, and comminuting them to form the fibrids.

Abstract: This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds that are antagonists of the progesterone receptor having the structure: wherein: R1 and R2 are (i) H, OH, OAc, alkylaryl, alkylheteroaryl, 1-propynyl, 3-propynyl, and optionally substituted alkyl, O(alkyl), aryl, or heteroaryl; (ii) a ring or (iii) a double bond; R3 is H, OH, NH2, CORA; or optionally substituted alkenyl or alkynyl; RA=H or optionally substituted alkyl, alkoxy, or aminoalkyl groups; R4=H, halo, CN, NH2, or optionally substituted alkyl, alkoxy, or aminoalkyl; R5 is a benzene ring; heterocyclic ring; an indole or benzothiophene; or pharmaceutically acceptable salt. R6 and R7 are H, methyl, ethyl, propyl, butyl, iso-propyl, isobutyl, cyclohexyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl.

Abstract: A piston pump having a piston axially movable against the force of a spring within an operating chamber connected via check valves to an operating cylinder and a hydraulic medium supply. A section of the piston that extends into the operating chamber has a reduced diameter extension which extends from a shoulder of the piston that delimits the operating chamber. The extension includes a thickened free end having a sealing surface facing the shoulder. A valve disk is located and guided on the extension in a gap between the shoulder and sealing surface and is capable of axially reciprocating movements thereon. The valve disk is provided with openings which provide a passageway for hydraulic medium from the operating chamber to a second check valve. The openings are blocked when the valve disk abuts the sealing surface.

Abstract: A ball screw comprising a screw shaft 1 made of steel and having a thread groove 6 on outer peripheral surface, a ball nut 2 made of steel and having a thread groove 7 opposing the thread groove 6 on inner peripheral surface, a return tube 3 attached on the ball nut 2, and a plurality of balls inserted between the two thread grooves 6 and 7 and in the return tube 3. As the balls, steel balls 4 made of bearing steel and ceramic balls 5 made of silicon nitride are disposed alternately at a given ratio. Diameter Dc of the ceramic ball 5 is set to a value smaller than diameter Ds of the steel ball 4 so that contact stress acted on contact surfaces of the ceramic ball 5 and the two thread grooves 6 and 7 will be equal to contact stress acted on contact surfaces of the steel ball 4 and the two thread grooves 6 and 7.

Abstract: This invention relates to cyclic combination therapies utilizing, in combination with progestins, estrogens, or both, compounds which are progesterone receptor antagonists of the general structure: wherein: R1 and R2 are H, CORA, or NRBCORA, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heterocyclic; or R1 and R2 fuse to form 3 to 8 membered spirocyclic alkyl, alkenyl or heterocyclic rings; RA is H or optionally substituted alkyl, aryl, alkoxy, or aminoalkyl groups; RB is H or alkyl; R3 is H, OH, NH2, CORC or alkyl, alkenyl, or alkynyl; RC is H, alkyl, aryl, alkoxy, or aminoalkyl; R4 is H, halogen, CN, NO2, alkyl, alkynyl, alkoxy, amino or aminoalkyl; R5 is benzene or 5- or 6-membered heterocyclic ring; R6 is H or alkyl; G1 is O, NR7, or CR7R8; G2 is CO or CR7R8; provided that when G1 is O, G2 is CR7R8, and G1 and G2 cannot both be CR7R8; R7 and R8 are H or an optionally substituted alkyl, aryl, or heterocyclic moiety; or pharmaceutically acceptable salt thereof.